Holoxan Uromitexan 200mg/1gm Injection is used to treat different cancers such as Blood, breast, non-small cell, ovarian, testicular, and pancreatic cancer. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. These cells can form tumours or spread to other body parts, interfering with normal function.

Holoxan Uromitexan 200mg/1gm Injection is a combination medication. It contains ifosfamide (antineoplastic agent) and mesna (cytoprotectants). Holoxan Uromitexan 200mg/1gm Injection works by damaging the genetic material (DNA and RNA) of cancer cells, stopping their growth and multiplication. 

Sometimes, you may experience specific side effects such as nausea, diarrhoea, vomiting, loss of appetite, headache, dizziness, hair loss, abdominal pain, pain or redness at the injection site, fever, sore throat, and cough. Most of these side effects will resolve gradually over time and do not require medical attention. However, consult the doctor if you experience these side effects persistently.

Consult your doctor if you are pregnant or breastfeeding. Holoxan Uromitexan 200mg/1gm Injection may cause dizziness. Therefore, avoid driving or operating heavy machinery unless you are fully alert. Holoxan Uromitexan 200mg/1gm Injection is safe for children if prescribed by the doctor. Holoxan Uromitexan 200mg/1gm Injection should not be given to children as its safety and efficacy have not been established. Consumption of alcohol is not recommended while receiving this Holoxan Uromitexan 200mg/1gm Injection as it may increase the risk of adverse effects such as dizziness, drowsiness, abnormal muscle movements, and seizures. Inform your doctor about your pre-existing medical conditions and if you are taking any other medications to prevent potential side effects.

Holoxan Uromitexan 200mg/1gm Injection will be administered by a healthcare professional through the Intravenous route. Do not self-administer.

Holoxan Uromitexan 200mg/1gm Injection belongs to the group of medicines called antineoplastic agents. Holoxan Uromitexan 200mg/1gm Injection is a combination of two drugs, Ifosfamide (antineoplastic agent) and mesna (cytoprotectants), used to treat different kinds of cancers such as blood cancer, breast cancer, non-small cell lung cancer, ovarian cancer, testicular cancer, and pancreatic cancer. Holoxan Uromitexan 200mg/1gm Injection works by damaging the genetic material (DNA and RNA) of the cancer cells. This stops their growth and multiplication. Mesna is used along with ifosfamide to protect the bladder from toxic side effects, particularly haemorrhagic cystitis.

Holoxan Uromitexan 200mg/1gm Injection should not be administered to individuals if they are allergic to it or its ingredients. Women of childbearing age should use effective birth control during treatment and for at least six months after the last dose to avoid pregnancy. Regular urine and blood tests, including CBC, are required to monitor blood cell counts while receiving Holoxan Uromitexan 200mg/1gm Injection. Holoxan Uromitexan 200mg/1gm Injection is not intended for use in conditions like haematuria due to thrombocytopenia or other underlying diseases. It may cause blurry vision and dizziness; therefore, avoid driving or operating heavy machinery while treating with Holoxan Uromitexan 200mg/1gm Injection. Inform your doctor if you have a history of kidney, heart, liver disease, cystitis, or CNS toxicity before starting therapy with Holoxan Uromitexan 200mg/1gm Injection. Avoid the consumption of alcohol as it may cause interactions and lead to unpleasant side effects. Holoxan Uromitexan 200mg/1gm Injection is unsafe during pregnancy and breastfeeding. Patients with infections should exercise caution, and chemotherapy may be temporarily stopped if fever or signs of infection occur. Holoxan Uromitexan 200mg/1gm Injection may cause bone marrow suppression, decreasing white blood cells and platelets, so regular monitoring is essential.